Tg Therapeutics (TGTX) Net Cash Flow (2011 - 2026)

Tg Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at $363.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 860.34% year-over-year to $363.1 million; the TTM figure through Mar 2026 stood at $310.1 million (up 447.19% YoY), while the FY2025 annual figure was -$100.7 million, down 215.78% from the prior year.
• Net Cash Flow was $363.1 million for Q1 2026 at Tg Therapeutics, up from $5.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $363.1 million in Q1 2026 to a low of -$113.2 million in Q1 2022.
• Historically, Net Cash Flow has averaged $8.4 million across 5 years, with a median of -$15.9 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow tumbled 667.56% in 2023, then jumped 860.34% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$7.6 million in 2022, then sank by 667.56% to -$58.0 million in 2023, then soared by 72.53% to -$15.9 million in 2024, then surged by 131.9% to $5.1 million in 2025, then soared by 7047.07% to $363.1 million in 2026.
• The last three Net Cash Flow figures came in at $363.1 million (Q1 2026), $5.1 million (Q4 2025), and -$55.0 million (Q3 2025), per Business Quant data.